Loading cancer entity…
Loading cancer entity…
Clinical trials
4,037 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (703)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT03181815 | Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 5 | Wake Forest University Health SciencesOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) | terminated | Phase 2 / Phase 3 | 344 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | terminated | Phase 2 | 1 | Mayo ClinicOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04043676 | Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 40 | Fundación Teófilo Hernando, SpainOTHER | 1 | Aug 2, 2019 | clinicaltrials |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | terminated | Phase 2 | 57 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT04015024 | A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00510133 | A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 21 | Asterias Biotherapeutics, Inc.INDUSTRY | 1 | Jul 9, 2019 | clinicaltrials |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS(DNKI-4) | terminated | Phase 2 | 77 | Asan Medical CenterOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT00946270 | Pomalidomide for Myelofibrosis Patients | completed | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2019 | clinicaltrials |
| NCT01294618 | Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia(NILOPEG) | completed | Phase 2 | 60 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00475020 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | completed | Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML)(AMLCTL) | terminated | Phase 1 / Phase 2 | 6 | Thomas A. Lane, MDOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 2 | 4 | Steven E. CoutreOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | terminated | Phase 2 | 32 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | terminated | Phase 2 | 16 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation | terminated | Phase 2 | 4 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia | withdrawn | Phase 2 | 0 | Matinas BioPharma Nanotechnologies, Inc.INDUSTRY | 0 | Mar 8, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02076191 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | completed | Phase 1 / Phase 2 | 49 | John MascarenhasOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | withdrawn | Phase 1 / Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00416598 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 546 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)(EFFIKIR) | completed | Phase 2 | 152 | Innate PharmaINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | terminated | Phase 1 / Phase 2 | 25 | Viron Therapeutics IncINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Aug 26, 2019source: clinicaltrials